Shots:

• MD Anderson to receive payments based on the development and commercialization of Schrödinger’s WEE1 inhibitor compounds. Schrödinger to provide research funding & will unite with researchers in MD Anderson's TRACTION platform to accelerate the development of new therapies
• Schrödinger will be responsible to develop- manufacture & commercialize the products & gets the rights to all novel intellectual property
• The focus of the collaboration is to accelerate & optimize the development of the WEE1 program through molecular biomarker-driven tumor type prioritization- patient stratification & validate biomarkers to predict response or resistance to a WEE1 inhibitor

  | Ref: Businesswire | Image: Businesswire